Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia

Abstract

Aim The aim of this study was to test small dense LDL changes with Armolipid Plus treatment in patients with familial combined hyperlipidemia (FCHL). Methods After 4 weeks, 30 patients with FCHL were included in an 8-week, randomized, double-blind study and were taking, in addition to the standard diet, either placebo or Armolipid Plus. Results The placebo group showed no statistically significant differences in the studied parameters; instead, in the Armolipid Plus group, statistically significant reduction differences were detected in BMI (p = 0.010), LDL score (p = 0.035) and an increase in mean LDL particle diameter (p = 0.040). Conclusion The combination of a standard diet with Armolipid Plus is able to reduce LDL score and increase LDL particle diameter in a group of FCHL after 8 weeks of treatment.

Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome

“…In the meta-analysis by Ho et al, oral treatment with 100 mg/day of coenzyme Q10 decreased SBP by 11 mmHg and DBP by 7 mmHg in subjects with HT [36]. However, the dose of coenzyme Q10 tested is 30 mg and higher than other NCs [37], and in part this explains its possible BP-lowering effect. However, CoQ10 has shown to significantly lower both SBP and DBP also in patients receiving conventional antihypertensive drugs [13] and in patients with isolated systolic hypertension [38].…”

Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

“…An additional 7 studies were excluded because of a lack of a controlled design for Armolipid Plus ® administration (n = 3) or lack of blinding (n = 4). Finally, 12 studies were eligible and included in the meta-analysis [26][27][28][29][30][31][32][33][34][35][36][37]. The study selection process is shown in Figure 1.…”

“…Follow-up periods ranged between 4 weeks and 12 months. All selected trials were designed with parallel groups and were multicenter [29,35,37] or single-center [26][27][28][30][31][32][33][34]36] clinical studies. Enrolled subjects were patients in primary prevention for CVD [28][29][30]32,36], patients with documented coronary artery disease (CAD) [33], with a metabolic syndrome [26,30,[34][35][36], or with a good status of health [28,37].…”

The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review

“…The results showed that Armolipid Plus® significantly decreased the LDL score compared with baseline and with the placebo group. Whilst mean LDL size significantly increased in the Armolipid Plus® group from baseline, there was no difference compared to placebo [122]. In another placebo-controlled trial, 147 individuals with metabolic syndrome were randomized into two groups, the intervention group received one tablet daily of Armolipid Plus® whilst the control group received a placebo tablet (microcrystalline cellulose, iron oxide brown) for 24 weeks.…”